Analyst Jill Wu of CMB International Securities maintained a Buy rating on Hansoh Pharmaceutical Group Company Limited (3692 – Research Report), retaining the price target of HK$25.24.
Jill Wu’s rating is based on several key factors that highlight the growth potential and strategic positioning of Hansoh Pharmaceutical Group. The company’s financial performance in FY24 was robust, with notable revenue and net income growth, driven by a significant increase in sales of innovative drugs. This trend is expected to continue, with projections indicating that sales of these drugs will surpass RMB10.0bn in FY25, demonstrating Hansoh’s strong market position.
Another critical factor is the success of Hansoh’s aumolertinib, which has shown substantial sales growth and benefits from its inclusion in the National Reimbursement Drug List (NRDL) for multiple indications. The company is actively working on expanding its indications, which is expected to further boost its market presence. Additionally, Hansoh’s strategic overseas out-licensing deals, such as those with GSK and MSD, are anticipated to provide a sustainable profit stream. These factors collectively support the Buy rating, as they indicate a promising outlook for Hansoh’s continued growth and profitability.
According to TipRanks, Wu is a 4-star analyst with an average return of 9.3% and a 56.38% success rate. Wu covers the Healthcare sector, focusing on stocks such as BeiGene, Thermo Fisher, and CSPC Pharmaceutical Group.